Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
    1.
    发明授权
    Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same 有权
    己基-5-氨基乙酰丙酸盐酸盐的形式及其使用方法

    公开(公告)号:US08927761B2

    公开(公告)日:2015-01-06

    申请号:US13930497

    申请日:2013-06-28

    摘要: This invention relates to a novel crystalline polymorph of hexyl-5-aminolevulinate hydrochloride, referred to hereinafter as Form C, which is useful as precursor of a photo sensitizer in the photodynamic diagnosis and treatment of metabolically active cells related to diseases such as cancer of the uterus, cervix, vagina, rectum, colon, lower gastrointestinal tract; infection associated with cancer caused by human papilloma virus; non-cancerous lower gastrointestinal tract a human; inflammatory bowel disease; ulcerative colitis; Crohn's disease; inflammatory bowel syndrome; dysplasia of the female reproductive system; anus; penis; rosacea; and acne and which is suitable for use as the active ingredient of a commercial pharmaceutical product. The invention relates further to methods of preparing Form C and using it in the described pharmaceutical compositions.

    摘要翻译: 本发明涉及一种新型的5-己基-5-氨基乙酰丙酸盐酸盐的结晶多晶型物,以下称为C型,其可用作光致敏剂的前体,用于光动力学诊断和治疗与诸如癌症的疾病相关的代谢活性细胞 子宫,子宫颈,阴道,直肠,结肠,下胃肠道; 与人乳头状瘤病毒引起的癌症相关的感染; 非癌性下胃肠道一人; 炎症性肠病; 溃疡性结肠炎 克罗恩病; 炎性肠综合征; 女性生殖系统发育异常; 肛门; 阴茎 红斑痤疮 和粉刺,并且其适合用作商业药物产品的活性成分。 本发明进一步涉及制备形式C并将其用于所述药物组合物中的方法。

    Solid state forms of racemic ilaprazole
    2.
    发明授权
    Solid state forms of racemic ilaprazole 有权
    外消旋伊拉唑的固体形式

    公开(公告)号:US08592600B2

    公开(公告)日:2013-11-26

    申请号:US12939276

    申请日:2010-11-04

    IPC分类号: C07D401/12

    CPC分类号: C07D401/14

    摘要: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译: 本发明涉及外消旋的伊拉唑,2 [[(4-甲氧基-3-甲基-2-吡啶基) - 甲基]亚磺酰基] -5-(1H-吡咯-1-基)1H-苯并咪唑的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物,其包含有效抑制胃酸分泌的量的本发明的伊拉唑结晶形式和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道(GI)障碍的方法。

    NOVEL FORMS OF CDDO METHYL ESTER
    5.
    发明申请
    NOVEL FORMS OF CDDO METHYL ESTER 有权
    CDDO甲基酯的新形式

    公开(公告)号:US20090048204A1

    公开(公告)日:2009-02-19

    申请号:US12191176

    申请日:2008-08-13

    CPC分类号: A61K31/70

    摘要: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

    摘要翻译: 三萜化合物,2-氰基-3,12-二氧杂环戊烯-1,9(11) - 二烯-28-甲酸甲酯(CDDO甲酯)具有非结晶的玻璃状固体形式和非水合结晶形式, 可以例如由饱和甲醇溶液制备。 玻璃状的形式显示了非含水结晶形式的增强的生物利用度。 每种形式的CDDO甲酯是通常用于固体剂型的优选候选药物,用于治疗通常与炎症相关的各种疾病状态。

    Forms of CDDO methyl ester
    9.
    发明授权
    Forms of CDDO methyl ester 有权
    形式的CDDO甲酯

    公开(公告)号:US08088824B2

    公开(公告)日:2012-01-03

    申请号:US12191176

    申请日:2008-08-13

    IPC分类号: A61K31/21

    CPC分类号: A61K31/70

    摘要: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

    摘要翻译: 三萜化合物,2-氰基-3,12-二氧杂环戊烯-1,9(11) - 二烯-28-甲酸甲酯(CDDO甲酯)具有非结晶的玻璃状固体形式和非水合结晶形式, 可以例如由饱和甲醇溶液制备。 玻璃状的形式显示了非含水结晶形式的增强的生物利用度。 每种形式的CDDO甲酯是通常用于固体剂型的优选候选药物,用于治疗通常与炎症相关的各种疾病状态。